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Background: Drug combination therapy is the frontline of malaria treatment. There is an ever-accelerating need for
new, efficacious combination therapies active against drug resistant malaria. Proven drugs already in the treatment
pipeline, such as the quinolines, are important components of current combination therapy and also present an
attractive test bank for rapid development of new concepts.
Methods: The efficacy of several drug combinations versus chloroquine-sensitive and chloroquine-resistant strains
was measured using both cytostatic and cytocidal potency assays.
Conclusions: These screens identify quinoline and non-quinoline pairs that exhibit synergy, additivity, or
antagonism using the fixed-ratio isobologram method and find tafenoquine – methylene blue combination to be
the most synergistic. Also, interestingly, for selected pairs, additivity, synergy, or antagonism defined by quantifying
IC50 (cytostatic potency) does not necessarily predict similar behaviour when potency is defined by LD50 (cytocidal
potency). These data further support an evolving new model for quinoline anti-malarials, wherein haem and
haemozoin are the principle target for cytostatic activity, but may not be the only target relevant for cytocidal
activity.
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Malaria remains a very serious threat to global health,
with 300–500 million clinical cases and nearly 1 million
deaths annually [1]. Given the growing spread of resist-
ance to current anti-malarial drugs and lack of an effect-
ive vaccine [1-4], development of novel, cost-effective,
and efficacious drugs is of utmost importance. Decades
of use of drugs such as chloroquine (CQ) have rendered
several cost-effective quinoline monotherapies ineffective
in various malaria endemic regions. For these reasons
and others, the WHO currently recommends combin-
ation therapies, particularly artemisinin (ART)-based
combination therapy (ACT), as first-line treatment for
uncomplicated Plasmodium falciparum [5]. Currently
valuable ACT consists of ART or derivatives, such as* Correspondence: roepep@georgetown.edu
1Department of Chemistry, Department of Biochemistry, Cellular, & Molecular
Biology, and Center for Infectious Disease, Georgetown University, 37th and
‘O’ Sts. NW, Washington, DC 20057, USA
Full list of author information is available at the end of the article
© 2013 Gorka et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the ordihydroartemisinin, artemether, and artesunate, in combin-
ation with longer half-life quinolines, such as amodiaquine
(AQ), mefloquine (MQ), or quinine (QN), antibiotics such
as doxycycline and clindamycin, or the blood schi-
zonticide lumefantrine [2,4,5]. Addition of a single dose
of the 8-aminoquinoline primaquine (PQ) to ACT is
also recommended given its transmission blocking and
gametocytocidal properties [5-7].
PQ was initially developed as a safer and more effect-
ive 8-aminoquinoline alternative to plasmoquine, and is
the only member of that drug class currently in use
[6,7], although clinical trials with the related drug
tafenoquine (TQ) are ongoing. PQ exhibits asexual stage
activity against Plasmodium vivax [8], kills hypnozoites of
P. vivax and Plasmodium ovale [9,10], and is active against
late-stage gametocytes of P. falciparum [6,7,11-13]. Stud-
ies have consistently shown that PQ can block transmis-
sion prior to the number of gametocytes being reduced
[14-16]. PQ has poor growth inhibitory activity against
intraerythrocytic stages of P. falciparum [17,18], likelytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in vitro [19-23] and an inability to bind ferriproto-
porphyrin IX (FPIX) haem in solution [20].
Use of PQ is limited by short plasma half-life and tox-
icity, principally haemolysis in patients with X-linked
glucose-6-phosphate dehydrogenase (G6PD) deficiency
[6,7], which varies between 3% and 30% in endemic areas
[24]. Recent evidence has suggested that risk of PQ ad-
ministration in high G6PD-deficient populations might be
ameliorated by lower dosing, without loss of game-
tocytocidal potency [25,26], which might be due to PQ
rapidly metabolizing to carboxyPQ, with plasma concen-
trations of the metabolite 10-fold greater than PQ 4 h
post-dosing [27]. Tafenoquine (TQ) (WR238605), a 5-
phenoxyl derivative of PQ [28], has improved asexual
stage activity [29], a significantly elongated plasma half-life
(two weeks vs 6 h) [27,30], and a greater therapeutic
index [31]. The compound remains haemolytic in
G6PD-deficient individuals, though to a lesser extent
than PQ [7].
In addition to use with current ACT, coadministration
of 8-aminoquinolines with blood schizonticides like CQ
and QN have been explored for their anti-relapse and
toxicity-reducing effects (see [32] for review). The latter
may be due to competition between the 8-aminoquinoline
and the coadministered agent for cytochrome P450s,
oxidases, or other metabolic enzymes [32]. Bray et al.
reported that PQ and TQ act synergistically with CQ
in vitro against the CQ resistant (CQR) K1 strain, with no
effect observed against the CQ sensitive (CQS) D10 strain
[33], and that PQ analogues lacking the aminoalkyl side
chain of PQ do not synergize with CQ. While this syner-
gistic effect has not been quantified clinically or in vivo,
there is some preliminary evidence that CQ combined
with PQ can lead to decreased treatment failure rates
against uncomplicated CQR P. falciparum [34,35]. PQ-
CQ synergy has also been proposed in treatment of CQR
cases of P. vivax in Thailand [8,36].
The thiazine dye methylene blue (MB) was the first
synthetic compound ever used in the treatment of dis-
ease [37], and there has recently been a resurgence of
interest in the anti-malarial properties of MB. The com-
pound appears to have transmission-blocking effects via
potent clearance of late-stage gametocytes [38], high
blood schizonticidal activity [38-40], and Hz inhibition
potential [41,42], presumably due to accumulation in the
digestive vacuole (DV) [38,42] and/or redox-cycling po-
tential [41,43-45]. MB has been observed to inhibit para-
site glutathione reductase (GR) [46,47], which could in
theory enhance activity of drugs such as CQ that cause
oxidative damage (see also [48]). However, Akoachere
et al. demonstrated that CQ and MB act antagonistically
against 3D7 (CQS) and K1 (CQR) strains [39]. Garavito
et al. later reported this combination to be additiveagainst strain FcM29 (CQR) [40]. Antagonism has also
been reported in the field [49,50], however, combination
use with ARTs and AQ have proven effective [50,51]. Re-
gardless, in in vitro studies, efficacy of these and other
drug combinations has been via standard P. falciparum
growth inhibition assays. No previous studies of drug
combination effects have explicitly quantified potency in
terms of cytocidal (parasite cell killing) activity.
Given the importance of combination therapy and the
attractiveness of further development of combinations
using proven, cost-effective, and widely-available drugs
like CQ, PQ, and MB (Figure 1), the effects of potentially
interesting drug combinations on in vitro antiplasmodial
cytostatic and cytocidal activity are investigated for both
a CQS and CQR strain of P. falciparum. Use of
isobologram-based approaches (see Methods) resolves
conflicting accounts of synergy, additivity, and antagon-
ism [33,39,40], and probes the relationships between
these parameters at cytostatic vs cytocidal dosages [19,52].
The results suggest an important new concept relevant for
the discovery of efficacious combination therapies.Methods
Materials and chemicals
Routine chemicals, media, and solvents were reagent
grade or better, purchased from Sigma-Aldrich (St. Louis,
MO, USA) or Fisher Scientific (Newark, DE, USA), and
used without further purification, unless otherwise noted.
Sterile black flat bottom tissue culture, or non-sterile clear
polystyrene 96-well plates, and all other laboratory plastics
were from Fisher Scientific (Newark, DE). SYBR Green I
nucleic acid stain was from Invitrogen (Eugene, OR,
USA). Anti-malarial drugs AQ dihydrochloride dihydrate,
CQ diphosphate, MB hydrate, PQ bisphosphate, and TQ
succinate were from Sigma-Aldrich (St. Louis, MO, USA).Parasite culture
Plasmodium falciparum clones HB3 (Honduras, CQS),
Dd2 (Indochina, CQR), and FCB (Thailand/S. Africa) were
obtained from the Malaria Research and Reference Reagent
Resource Center (Manassass, VA, USA). Off-the-clot, heat-
inactivated pooled type O+ human serum and type O+
human whole blood were purchased from Biochemed Ser-
vices (Winchester, VA, USA). Custom 5% O2/5% CO2/
90% N2 gas blend was purchased from Robert’s Oxygen
(Rockville, MD, USA).
Plasmodium falciparum strains were maintained using
the method of Trager and Jensen [53] with minor modi-
fications. Briefly, cultures were maintained under an
atmosphere containing 5% CO2, 5% O2, and 90% N2 gas-
eous mix at 2% haematocrit and 1-2% parasitaemia in
RPMI 1640 supplemented with 10% type O+ human
serum, 25 mM HEPES (pH 7.4), 23 mM NaHCO3,
Figure 1 Structures of anti-malarial drugs used in this study.
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gentamicin, with regular media changes every 48 h.
Anti-plasmodial assays
Anti-plasmodial cytostatic (growth inhibitory, quantified
by the half-maximal growth inhibitory dose or IC50) and
cytocidal (cell killing, quantified by the half-maximal lethal
dose or LD50) activity was assessed against the above
strains as previously described [52,54], with minor modifi-
cations. The cytocidal assay utilizes a 6 h bolus dose with
high concentrations of drug followed by washing drug
away and growth in the absence of drug for 48 h, while
the cytostatic assay utilizes continuous growth for 48 h in
the constant presence of low concentrations of drug. Test
compounds were dissolved in deionized water, 50% etha-
nol, or dimethyl sulfoxide. Serial drug dilutions were made
using complete media and 100 μL aliquots were trans-
ferred to 96-well clear-bottom black plates. Following
addition of 100 μL of asynchronous culture (1% final para-
sitaemia, 2% final haematocrit), plates were transferred to
an airtight chamber, gassed with 5% CO2/5% O2/90% N2
and incubated at 37°C.
For the cytocidal assay, plates were incubated for 6 h
followed by centrifugation with an Eppendorf 5804centrifuge fitted with an A-2-DPW rotor (Hauppauge,
NY) at 700 g for 3 min [52]. Drug-containing media was
removed and cell pellets washed three times with 200 μL
of complete media per wash, using the same centrifuge
settings, and re-suspended in the same volume of media.
Washed plates were incubated side by side with the cy-
tostatic assay plates at 37°C for 48 h. After 48 h, 50 μL
of 10X SYBR Green I dye (diluted using complete media
from a 10,000X DMSO stock) was added and plates
incubated for an additional 1 h at 37°C to allow DNA
intercalation. Fluorescence was measured at 538 nm
(485 nm excitation) using a Spectra GeminiEM plate
reader (Molecular Devices; Sunnyvale, CA) fitted with a
530 nm long-pass filter. Linear standard curves of mea-
sured fluorescence vs known parasitaemia were prepared
immediately prior to plate analysis. Background controls
included fluorescence from un-infected red blood cells.
Data was analysed using MS Excel 2007 and IC50 and LD50
values obtained from sigmoidal curve fits to % growth/sur-
vival vs drug concentration data using SigmaPlot 11.0.
Reported values are the average of three independent as-
says, with each assay conducted in triplicate (nine determi-
nations total) and reported ± standard error of the mean
(S.E.M.), unless otherwise noted.
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The effect of drug combinations was assessed using the
modified fixed-ratio isobologram analysis protocol [55]
(hereafter referred to as “isobologram analysis”), with
some modification. This method detects synergy, addi-
tivity, or antagonism between a drug pair. In general, if
the drug pair has improved IC50 or LD50 potency relative
to each drug alone, the combination is synergistic, if po-
tency remains unchanged the effect is additive, and if
potency is reduced the effect is antagonistic.
Master stock drug solutions were prepared for each
drug using complete media, such that the final concen-
tration approximates IC50 or LD50 following 5–6 twofold
dilutions [39,56,57]. Using these master stocks, the fol-
lowing volume-volume (v/v) mixtures of “Drug A” and
“Drug B” were prepared: 0:4, 1:3, 1:1, 3:1, and 4:0. These
mixtures were then two-fold serially diluted to generate
a range of 8 concentrations in each case. Standard cyto-
static or cytocidal antiplasmodial assay conditions (see
above) were then followed to provide a dose response
curve, and IC50 or LD50 for Drug A and Drug B in each
v/v mixture was calculated [33,39,55-61]. Fractional in-
hibitory concentrations (FICs) were then calculated
using Equations 1, 2 and 3 [39,55-57].
FICA ¼ IC50 of Drug A in CombinationIC50 of Drug A Alone ð1Þ
FICB ¼ IC50 of Drug B in CombinationIC50 of Drug B Alone ð2Þ
FICindex ¼ FICA þ FICB ð3Þ
Isobologram curves were constructed by plotting FICB
vs FICA. A straight diagonal line (FICindex = 1) indicates an
additive effect between Drug A and Drug B [39,55-57],
concave below the diagonal (FICindex < 1) indicates a syn-
ergistic effect and a convex curve above the diagonal
(FICindex > 1) indicates antagonism.
Results
Similar to previous analyses of CQ, QN, QD, MQ and
series of CQ and QN analogues [19,20,52], significantTable 1 Anti-plasmodial activity data
Experimental IC50
a (nM)
Drug HB3 Dd2 Rf
b
CQ 23.8 (0.7) 212.3 (9.0) 9.0
AQ 10.1 (0.6) 26.5 (0.4) 2.6
PQ 1990.0 (16.6) 4695.0 (62.1) 2.4
TQ 2189.9 (18.7) 2092.2 (20.0) 1.0
MB 5.3 (0.09) 5.5 (0.07) 1.0
aAverage of 3 independent measurements, each performed in triplicate (9 determin
bResistance factor (Rf) = Dd2 value/HB3 value.differences in cytostatic (IC50) and cytocidal (LD50) po-
tency are observed for test compounds used in this work
(Table 1, see also Additional files 1 and 2). Also similar
to previous work [52], differences in drug sensitivity for
CQS strain HB3 vs CQR strain Dd2 are not of similar
magnitude when potency is defined via IC50 vs LD50. For
example, Dd2 is 2.4-fold resistant to PQ via IC50 but ap-
proximately three-fold more sensitive via LD50 (Table 1).
Dd2 shows similar cytostatic sensitivity to TQ compared
to HB3, but interestingly is nearly four-fold more sensitive
to cytocidal effects of TQ (Table 1). As reported previ-
ously, CQR Dd2 is 10-fold cytostatic CQR (“CQRCS”) but
over 100-fold cytocidal CQR (“CQRCC”) [52]. In contrast
the related 4-aminoquinoline AQ shows similar potency
against both strains, under either cytostatic or cytocidal
assay conditions, which is quite rare behaviour for a quin-
oline anti-malarial drug based on previous examination of
many quinoline compounds [19,20,52]. Similar to AQ,
MB is quite active relative to quinolines under both cyto-
static and cytocidal conditions and shows no major differ-
ences between HB3 and Dd2, making it a promising lead
compound vs CQR P. falciparum.
Results of IC50- and selected LD50-based isobologram
analyses of these drugs in various combinations are
shown in Figures 2 and 3 (see also Additional files 1, 2
and 3), with antagonism, additivity, and synergy findings
summarized in Table 2. In contrast to Bray et al. [33]
but in agreement with Akoachere et al. [39], the com-
bination of CQ-PQ is antagonistic against HB3 (CQS)
(black curve, Figure 2 top left) and additive against Dd2
(CQR) when potency is defined by IC50 (black curve,
Figure 2 top right). This combination is strongly antagon-
istic against both strains when potency is defined by LD50
(Figure 3, black curves). IC50 antagonism is observed with
the CQ-TQ combination against both strains (red curves,
Figure 2 top) in contrast to synergy seen against the K1
strain (SE Asia, CQR) [33]. AQ combined with PQ is an-
tagonistic against both strains by IC50. AQ-TQ is additive
against HB3, but antagonistic against Dd2 (orange curves,
middle panels Figure 2). CQ-AQ is cytostatically additive
for both strains (Figure 2), but exhibits significant antag-




120.0 (10.0) 15300.0 (900.0) 127.5
37.2 (1.2) 52.4 (2.3) 1.4
8640.0 (50.0) 2810.0 (10.0) 0.3
42700.0 (2042.6) 12100.0 (706.0) 0.3
120.2 (9.5) 108.0 (6.6) 0.9
ations total), with S.E.M. reported in parentheses.
Figure 2 IC50-based isobologram curves against HB3 (CQS, left column) and Dd2 (CQR, right column) for combinations with CQ (top),
AQ (middle), and PQ/TQ (bottom) as “drug A” (x-axes). CQ-PQ (black), CQ-TQ (red), CQ-MB (green), CQ-AQ (pink), AQ-PQ (dark blue), AQ-TQ
(orange), AQ-MB (gray), PQ-MB (purple), and TQ-MB (light blue or cyan). FICA and FICB correspond to the fractional inhibitory concentrations (see
Methods) of the first and second drugs in each pair listed above, respectively. Error bars represent the standard error of the mean (S.E.M.) for
duplicate experiments, each performed in triplicate (6 determinations total).
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and additivity seen under cytostatic assay conditions are
not necessarily conserved under cytocidal assay condi-
tions. Similar to related conclusions based on multidrug
resistance patterns [52] or drug accumulation studies [62],
these data further highlight that the mechanism(s) of anti-
malarial drug parasite growth inhibition and parasite cell
kill are not necessarily the same, and that molecular tar-
gets for the cytostatic vs cytocidal activities of some im-
portant anti-malarial drugs likely differ.
The IC50 antagonism observed for CQ-AQ, CQ-MB
and AQ-MB combinations is in agreement with previousstudies [33,40], except that in the case of AQ-MB,
Garavito et al. previously measured additive effects for
these two drugs against the FcM29 strain (Cameroon,
CQR) [40]. IC50 antagonism is also observed with PQ-
MB against HB3, but additivity is seen against Dd2, in
agreement with Garavito et al. [40]. Finally, with the ex-
ception of IC50 additivity against HB3 (Figure 2 bottom
left), excellent synergy is seen between TQ and MB
under both cytostatic and cytocidal conditions, with
synergy being significantly greater in the latter case
(Figure 2). Importantly then, some drug combinations
may show potent cytostatic and cytocidal synergy for
Figure 3 LD50-based isobologram curves for HB3 (CQS, left) and Dd2 (CQR, right). CQ-PQ (black), CQ-AQ (pink), and TQ-MB (cyan). FICA and
FICB correspond to the fractional inhibitory concentrations (see Methods) of the first and second drugs in each pair listed above, respectively.
Error bars represent the standard error of the mean (S.E.M.) for duplicate experiments, each performed in triplicate (6 determinations total).
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concept for regions where CQR P. falciparum is
dominant.
To further explore one contrasting result between
these data and previous [33], the CQ-PQ and CQ-TQ
combinations were reexamined against the FCB1 strain.
This CQR strain from Thailand/S. Africa harbours the
same P. falciparum chloroquine resistance transporter
(PfCRT) amino acid mutations as K1 and has a similar
CQ IC50 [63] (see Additional files 4 and 5). Dd2, how-
ever, differs from these two strains in a mutation at
position 356, which is I in K1 and FCB1 but T in Dd2.
Mutations in the P. falciparum multi-drug resistance
protein (PfMDR1) are identical among these three
strains [64,65] (see Additional file 6). Results obtained
with FCB1 are similar to those obtained with HB3 and
Dd2, in that combination of CQ with either PQ or TQ
is antagonistic (Table 2, see also Additional file 5).Table 2 Summary of drug interactionsa
IC50-Based LD50-Based
Combination HB3 (CQS) Dd2 (CQR) HB3 (CQS) Dd2 (CQR)
CQ-PQ Antagonistic Additive Antagonistic Antagonistic
CQ-TQ Antagonistic Antagonistic - -
CQ-AQ Additive Additive Additive Antagonistic
CQ-MB Antagonistic Antagonistic - -
AQ-PQ Antagonistic Antagonistic - -
AQ-TQ Additive Antagonistic - -
AQ-MB Antagonistic Antagonistic - -
PQ-MB Antagonistic Additive - -
TQ-MB Additive Synergistic Synergistic Synergistic
aAntagonism is defined by a convex isobologram curve (FICindex > 1), additivity
by a isobologram curve along the diagonal (FICindex = 1), and synergy by a
concave isobologram curve (FICindex < 1) (Figure 2).Discussion
This study reports the first systematic analysis of quin-
oline anti-malarial drug combinations quantified for
both cytostatic and cytocidal potency. Recent studies
suggest that cytostatic and cytocidal mechanisms of ac-
tion for some anti-malarial drugs differ [19,20,52,62],
and the present data further support this concept. Com-
parative investigation of drug combinations under both
IC50 and LD50 conditions will enhance further develop-
ment of effective combination therapies and also in-
crease understanding of antimalarial drug pharmacology
and resistance. IC50 and LD50 data for the individual drugs
reinforces this concept (Table 1). Strain Dd2 is 10-fold re-
sistant to CQ (relative to strain HB3) when IC50 is ratio’d,
but over 100-fold resistant when LD50 values are ratio’d.
On the other hand, the closely-related 4-aminoquinoline
AQ has similar potency for both strains under both cyto-
static and cytocidal conditions, a characteristic also found
for ART (A. Gorka, P. Roepe, unpublished). MB, while
having nearly identical activity for the CQS and CQR
strains (behavior similar to AQ), is about 20-fold less po-
tent by LD50 relative to IC50 (unlike AQ). PQ, an 8-
aminoquinoline known to be a poor blood schizonticide
[17,18], is nonetheless active compared to CQ when po-
tency is defined by LD50 for CQR strain Dd2 (15.3 μM
CQ LD50 vs 2.8 μM PQ LD50, Table 1). In fact, Dd2 is
about three-fold hypersensitive to PQ relative to HB3
when LD50 are compared. Results for drug combinations
show significant differences in synergy, additivity, and
antagonism (Table 2), as well as in the shapes of their
isobologram curves (Figure 2). In general, cytocidal antag-
onism is significantly more pronounced relative to exam-
ples of cytostatic antagonism. Overall, these data offer
additional explanations for why in vitro IC50-based assess-
ment of mono- or combination therapy may not always
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cytocidal potencies are critical.
The CQ-PQ combination results in cytostatic antagon-
ism (CQS) and additivity (CQR), which disagrees with
data [33] for the CQR strain K1, where potent synergy
for CQ-PQ and CQ-TQ combinations was found. In
growth inhibition assays, as suggested [33], the combin-
ation effects may be PfCRT-dependent and rely on the
presence of the PQ/TQ basic side chain, as well as co-
administration of the drug pair [33]. As suggested [33],
due to their structural similarity to CQ but increased li-
pophilicity, PQ and TQ may bind with higher affinity to
the mutated pore of PfCRT and block passage of CQ
[33]. However, compared to strain Dd2, the K1 strain
(CQR, S.E. Asia) differs in a PfCRT mutation at position
356 (see Additional file 4) [63]. Although strain K1 was
not available for this study, CQ-PQ and CQ-TQ combi-
nations were re-tested against the FCB1 strain (CQR,
Thailand/S. Africa), which bears an identical set of
PfCRT [63] and PfMDR1 [64,65] mutations relative to
K1. These combinations again exhibited antagonism (see
Additional file 5), indicating altered CQ transport by
PfCRT may not be the only factor governing combin-
ation effects.
The closely-related 4-aminoquinoline AQ also showed
antagonism with PQ and TQ across all conditions, with
the exception of AQ-TQ against Dd2, which was additive.
Therefore, similar to the CQ combinations discussed
above, differences between cytostatic and cytocidal re-
sponse, as well as important differences between the CQS
and CQR strains are observed when AQ is a partner drug.
Further exploration of these concepts with other CQS and
CQR strains is vital. Combination of CQ with AQ was
purely additive against both strains by IC50 and against the
CQS strain by LD50 (Figures 2 and 3, Table 2). AQ is
expected to have a similar overall mechanism of action to
that of CQ under cytostatic conditions (e.g. inhibition of
Hz formation), so additive action of these two drugs in
combination is expected for IC50. Surprisingly though,
CQ-AQ exhibits significant antagonism against the
CQR Dd2 strain by LD50. In light of recent evidence
[19,20,52,62], this observation again points to the gen-
eral hypothesis that drug targets and the manner in
which the parasite facilitates resistance to those drugs
are different under cytocidal vs cytostatic conditions. In
investigating this further, future work will test for syn-
ergy, additivity, and antagonism for these drug pairs
against a wider range of strains harbouring different
CQR-associated PfCRT alleles.
CQ-MB was cytostatically antagonistic against both
strains, in agreement with Akoachere et al., who observed
antagonism against 3D7 (CQS) and K1 [39], but in
contrast to Garavito et al., who observed additivity against
the FcM29 strain (CQR, Cameroon) [40]. Antagonismbetween CQ and MB is surprising given the high blood
schizonticidal potency of MB, its potent inhibition of Hz
formation in vitro [41,42], and inhibition of parasite gluta-
thione reductase [46-48,66,67], as well as its ability to ac-
cumulate in the DV, similar to CQ [42]. However, such
antagonism has also been reported in the field, with fail-
ure of CQ and MB observed in treatment of uncompli-
cated malaria in young children in Burkina Faso [49,50].
AQ was also antagonistic with MB, in agreement with
Garavito et al. [40]. IC50 antagonism in such cases
might indicate distinctly different modes of haemozoin
precursor binding [68].Conclusions
Using a rigorous isobologram approach, cytocidal and
cytostatic anti-plasmodial potency have been determined
for various combinations of quinoline drugs and MB, for
both a CQS and CQR strain of P. falciparum. The re-
sults highlight differences in drug activity and resistance
under cytostatic vs cytocidal conditions. They also show
that antagonism or synergy found for a drug pair via
IC50 data (cytostatic activity) does not necessarily predict
the same behavior when potency for the pair is quanti-
fied via LD50 data (cytocidal activity). Furthermore, the
data help prioritize combinations that warrant further
exploration against CQR malaria (e.g. TQ-MB), vs those
with limited applicability (e.g. CQ-PQ). Important next
steps are to examine the correlation between anti-malarial
drug combination effects and Hz inhibition, as well as to
widen this cytostatic vs cytocidal profiling to other drugs,
active drug metabolites, and many geographic isolates of
P. falciparum.Additional files
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